NCT05831995 2024-12-06
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
ABM Therapeutics Corporation
Phase 1 Terminated
ABM Therapeutics Corporation
ABM Therapeutics Corporation
Cambridge University Hospitals NHS Foundation Trust
Tocagen Inc.